Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06423261
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-03
First Post:
2024-04-30
Brief Title:
Safety Tolerability Pharmacokinetics and Immunogenicity Study of GB002 Recombinant Peptide Inhalation Solution in Healthy Subjects
Sponsor:
Zhejiang Echon Biopharm Limited
Organization:
Zhejiang Echon Biopharm Limited
Study Overview
Official Title:
Phase I Clinical Study to Evaluate the Safety Tolerability Pharmacokinetics and Immunogenicity of GB002 Recombinant Polypeptide Inhalation Solution in a Randomized Double-blind Placebo-controlled Dose-increasing Single and Multiple Administration in Chinese Healthy Adult Subjects
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is conducted in China The purpose of this clinical trial is to evaluate the safety and tolerability pharmacokinetic PK characteristics and immunogenicity of singlemultiple inhalation of different doses of GB002 recombinant peptide in healthy subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None